Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib
Purpose To determine the frequency of ocular adverse effects associated with vemurafenib (PLX4032) treatment for metastatic cutaneous melanoma. Design Retrospective review of the clinical study reports from the clinical pharmacology,…